Managing Director

The North East and North Cumbria Provider Collaborative (NENC) proposes to establish a NENC Medicines Manufacturing Centre (MMC) at Seaton Delaval, as part of a hub and spoke model working across the NENC. We require a highly skilled, ambitious and motivated Managing Director to take on a hands-on senior leadership role, reporting directly to the Board, overseeing and advancing the Clinical and Commercial success of the Medicines Manufacturing Centre (MMC).

As newly emerging organisation, you will lead the implementation of the MMC. You'll be at the helm, crafting and executing strategies that ensure our production and delivery schedules meet the needs of our clients and their patients on time, every time. Collaborating with teams across Quality, Technical Operations, Project Management, Finance, and Business Development, you'll foster a client-focused, solution-oriented culture rooted in continuous improvement and lean methodologies.

At present the formal establishment of the LLP is awaiting the approval of national bodies. We are planning for this approval to be confirmed later this year. The successful applicant will be appointed by Northumbria Healthcare Foundation Trust, and following the approval of the formal establishment of the LLP, may be subject to Transfer of Undertakings (Protection of Employment) Regulations (TUPE) 2006 regulations, where required.

Main duties of the job

The successful applicant will be responsible for the following:

To establish and run the core functions of the MMC, delivering MHRA Licence requirements, corporate governance, commercial success and financial balance.

To work with partner organisations, and to represent the MMC on the LLP board.

To be responsible for the provision and management of medicines manufacturing services and contribute to the strategic development of these services across the region. Be a visible leader to support these services from now into the future.

To work with partner organisations across the LLP to ensure co-ordinated regional product/service provision where partner organisations may be delivering different products/services.

To provide represent to MMC at relevant national groups.

To represent the MMC and be accountable to the regional LLP board.

To hold corporate and statutory responsibility for obtaining, maintaining and delivering MMC manufacturing services in accordance with relevant MHRA licence requirements.

To be accountable to the LLP board for ensuring that safe, effective and cost effective quality systems are in place for the assurance of and operation of procurement of starting materials, manufacture /production, testing and distribution of medicines.

The MMC will be one of the largest NHS pharmacy manufacturing centres in the UK and is a critical part of the long-term strategy for NHS pharmacy production. It is anticipated the MMC will be managed via a Limited Liability Partnership (LLP) made up of the eight Trusts who currently provide aseptic products across the region. The key priority areas are:

1. Injectable chemotherapy medicines supply.

2. Addressing nursing time currently spent preparing injectable medicines

3. Provision of Over-labelling of medicines.

Regionally c.4 million injectable products are produced per annum. The MMC is projected to deliver c1.4 million products. The aggregate 10 year revenue budget is expected to be c. £750 million. MMC will employ c.150 staff across various roles including:Production, QA/QC, Warehousing, as well as corporate/support services.